Publications by authors named "Edwin Kingsley"

Claim this Profile
T
Tinengotinib for adults with advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 trial.
Milind Javle, Christos Fountzilas, Chih-Yi Liao, Meredith Pelster, Daneng Li, Edwin Kingsley

Lancet Gastroenterol Hepatol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomic landscape of patients in a phase II study of zanubrutinib in ibrutinib- and/or acalabrutinib-intolerant patients with B-cell malignancies.
Linlin Xu, Mazyar Shadman, Ian W Flinn, Moshe Y Levy, Ryan Porter, Edwin C Kingsley

Haematologica· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma.
Pier Luigi Zinzani, Jiří Mayer, Christopher R Flowers, Fontanet Bijou, Ana C De Oliveira, Edwin Kingsley

J Clin Oncol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Z
Zanubrutinib in patients with treatment-naïve or relapsed/refractory Waldenström macroglobulinemia: An expanded-access study of 50 patients in the United States.
Jorge J Castillo, Edwin C Kingsley, Mohit Narang, Habte A Yimer, Constantin A Dasanu

EJHaem· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Z
Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study.
Mazyar Shadman, Ian W Flinn, Moshe Y Levy, Ryan F Porter, John M Burke, Edwin C Kingsley

Lancet Haematol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of ofatumumab and bendamustine followed by ofatumumab maintenance in patients with relapsed indolent non-Hodgkin lymphoma after prior rituximab.
Roger M Lyons, Mikhail Shtivelband, Edwin Kingsley, Mehdi Moezi, Donald Richards

Leuk Lymphoma· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cancer survivorship in hematologic malignancies: Lifestyle changes after diagnosis.
Pannaga Malalur, Manas Agastya, Sandhya Wahi-Gururaj, Chad L Cross, Delva Deauna-Limayo, Edwin C Kingsley

Cancer Med· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non-germinal center B-cell-like DLBCL.
Andre Goy, Radhakrishnan Ramchandren, Nilanjan Ghosh, Javier Munoz, David S Morgan, Edwin Kingsley

Blood· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma.
Tycel Phillips, Paul M Barr, Steven I Park, Kathryn Kolibaba, Paolo F Caimi, Edwin C Kingsley

Invest New Drugs· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extended dosing with CC-486 (oral azacitidine) in patients with myeloid malignancies.
Michael R Savona, Kathryn Kolibaba, Paul Conkling, Edwin C Kingsley, Carlos Becerra

Am J Hematol· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma.
James R Berenson, James D Hilger, Ori Yellin, Ralph V Boccia, Jeffrey Matous, Edwin C Kingsley

Ann Hematol· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis